We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AFFiRiS will Explore ProBioGen’s Human Artificial Lymph Node Technology for Vaccine Testing
News

AFFiRiS will Explore ProBioGen’s Human Artificial Lymph Node Technology for Vaccine Testing

AFFiRiS will Explore ProBioGen’s Human Artificial Lymph Node Technology for Vaccine Testing
News

AFFiRiS will Explore ProBioGen’s Human Artificial Lymph Node Technology for Vaccine Testing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AFFiRiS will Explore ProBioGen’s Human Artificial Lymph Node Technology for Vaccine Testing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AFFiRiS AG will explore ProBioGen’s proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept.

Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans. Using the HuALN technology AFFiRiS anticipates accelerating the progression of its human vaccine candidates into clinical trials.

“We have been looking for a system like the Human Artificial Lymph Node for quite a long time and are excited by the possibilities the system offers to test our peptide vaccine candidates which are delivered by our proprietary AFFITOME® technology”, commented Walter Schmidt, CEO of AFFiRiS.

“AFFiRiS with its cutting-edge technology in the vaccine field is an ideal partner to further underline the strengths of ProBioGen’s HuALN technology. We are very much looking forward to this co-operation” said Michael Schlenk, CEO of ProBioGen.
Advertisement